吉西他滨联合奈达铂序贯化放疗治疗肺鳞癌74例临床分析

目的：探讨吉西他滨联合奈达铂序贯化放疗治疗肺鳞癌的临床应用。方法74例入选肺鳞癌患者随机分为实验组(n =37)和对照组(n =37)。对照组采用吉西他滨联合奈达铂化疗；实验组在化疗基础上采用三维适形放疗，化疗方案以21 d 为1个周期，接受4个周期化疗，化疗的第1周期同期对原发病灶进行三维适形放疗。观察患者近期临床疗效、生活质量改善情况及不良反应。结果2组患者全部完成治疗计划，实验组有效率为54.1%，疾病控制率为81.1%，疗效优于对照组(P <0.05)。实验组、对照组生活质量改善有效率为分别为73.0%、64.9%，组间比较差异无统计学意义(P >0.05)。2组主要不良反应为白细胞、血小板、血红蛋白下降及恶心呕吐，实验组患者放射性肺炎、放射性食管炎程度较轻，经对症处理后均可耐受。结论吉西他滨联合奈达铂序贯化放疗治疗肺鳞癌临床疗效显著，不良反应较轻，值得临床深入研究及推广应用。

Clinical analysis of gemcitabine combined with nedaplatin for sequential chemoradiotherapy in treatment of lung squamous cell carcinoma

Objective To investigate the clinical application of gemcitabine combined with nedaplatin for sequential chemoradiotherapy in the treatment of lung squamous cell carcinoma.Methods 74 selected patients with lung squamous cell carcinoma were divided into experimental group (n = 37) and control group (n = 37).Control group was treated with chemotherapy,experimental group was treated with chemotherapy and three dimensional conformal radiation therapy.Chemotherapy regimen took 21 days for one cycle,at the same time of first cycle of chemotherapy,three dimensional conformal radiotherapy was used for primary lesions.The clinical efficacy,improvement of life quality and adverse reactions were observed.Results The patients with lung squamous cell carcinoma all completed the treatment plan.The total effective rate of experimental group was 54.1%,and the disease control rate was 81.1%,which was superior to the control group with gemcitabine combined with nedaplatin chemotherapy.The effective rate of improvement of life quality in experimental group and control group was 73.0%,64.9% respectively,there was no significant difference between the two groups(P >0.05). The main adverse reactions of the two groups were the depression of white blood cell,platelet and hemoglobin and nausea and vomittin,gradiation pneumonitis and oesophagitis in experimental group were light and could be tolerated after symptomatic treatment.Conclusions Gemcitabine combined with nedaplatin for sequential chemoradiotherapy has remarkable clinical efficacy and less adverse reactions.It is worthy of clinical research and popularization.